Summary

The global pemphigus vulgaris market is expected to reach USD 809.71 million by 2032 from USD 419.49 million in 2024, growing at a CAGR of 8.7% in the forecast period of 2025 to 2032.
Market Segmentation:
Global Pemphigus Vulgaris Market Segmentation, By Diagnosis and Treatment (Diagnosis and Treatment), Population Type (Pediatric, Adults, and Geriatric), End User (Hospitals, Specialty Clinics, Research Institutes, and Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, and Online Pharmacy), Countries (U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Netherlands, Belgium, Denmark, Finland, Sweden, Switzerland, Norway, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Philippines, Malaysia, Indonesia, New Zealand, Taiwan, Hong Kong, Rest of Asia-Pacific, Brazil, Argentina, Colombia, Peru, Uruguay, Ecuador, Paraguay, Venezuela, Bolivia, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Kuwait, Bahrain, Israel, Oman, Qatar, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2032

Overview of Global Pemphigus Vulgaris Market Dynamics:

Driver

• Emerging treatment options for pemphigus vulgaris

Restraint
• Stringent regulatory guidelines for pemphigus vulgaris drug approval
Opportunity
• Increasing demand for personalized medicine

Market Players:

The key market players operating in the global pemphigus vulgaris market are listed below:

• Merck & Co., Inc. (U.S.)
• Sanofi (France)
• Regeneron Pharmaceuticals Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• AstraZeneca (U.K.)
• GRIFOLS SA (Spain)
• Zydus Group (India)
• F. Hoffmann-La Roche Ltd (Switzerland)
• GSK plc. (U.K.)
• Boehringer Ingelheim International GmbH (Germany)
• Celltrion (South Korea)
• Lilly (U.S.)
• Pfizer Inc. (U.S.)
• Abbvie Inc. (U.S.)
• Fresenius Kabi AG (Germany)
• Rakshit Drugs Private Limited (India)
• Amgen Inc (U.S.)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Artiva Biotherapeutics, Inc. (U.S.)
• Cabaletta Bio Inc. (U.S.)
• Incyte (U.S.)
• CSL (Australia)
• Baxter (U.S.)
• Accord Healthcare (U.K.)
• DAEWOONG PHARMACEUTICAL CO., LTD. (South Korea)
• SUNPHARMA.NS (India)
• OCTAPHARMA AG (Switzerland)
• Cipla Health Ltd (India)
• BioXpress Therapeutics SA (Switzerland)

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW 41
1.4 LIMITATIONS 42
1.5 MARKETS COVERED 43
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 CURRENCY AND PRICING 48
2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
2.6 MULTIVARIATE MODELLING 52
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.8 DBMR MARKET POSITION GRID 55
2.9 MARKET END USER COVERAGE GRID 56
2.10 VENDOR SHARE ANALYSIS 57
2.11 SECONDARY SOURCES 58
2.12 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 66
4.1 PESTAL ANALYSIS 68
4.2 PORTERS FIVE FORCES ANALYSIS 69
4.3 PATENT ANALYSIS 70
4.3.1 PATIENT FLOW DIAGRAM 71
4.3.2 KEY PRICING STRATEGIES 72
4.3.3 FUTURE THERAPIES 72
4.3.4 KEY PATIENT ENROLLMENT STRATEGIES 73
4.4 GLOBAL CLINICAL TRIAL MARKET FOR PEMPHIGUS VULGARIS MARKET 75
4.5 SUPPLY CHAIN ECOSYSTEM 81
4.6 HEALTHCARE TARIFFS & IMPACT ON THE MARKET: GLOBAL PEMPHIGUS VULGARIS MARKET 83
4.7 EPIDEMIOLOGY: GLOBAL PEMPHIGUS VULGARIS MARKET 86
4.7.1 INCIDENCE BY GENDER 86
4.7.2 TREATMENT RATE 86
4.7.3 MORTALITY RATE 86
4.7.4 PATIENT TREATMENT SUCCESS RATES 87
5 GLOBAL PEMPHIGUS VULGARIS MARKET: REGULATIONS 88
6 MARKET OVERVIEW 94
6.1 DRIVERS 96
6.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 96
6.1.2 RISING PREVALENCE OF AUTOIMMUNE DISORDERS 97
6.1.3 GROWING AWARENESS OF PEMPHIGUS VULGARIS 98
6.1.4 GROWING ADOPTION OF IMMUNOSUPPRESSIVE TREATMENTS 99
6.2 RESTRAINTS 100
6.2.1 STRINGENT REGULATORY GUIDELINES FOR PEMPHIGUS VULGARIS DRUG APPROVAL 100
6.2.2 HIGH TREATMENT COSTS FOR PEMPHIGUS VULGARIS THERAPIES 101
6.3 OPPORTUNITIES 102
6.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 102
6.3.2 INCREASING HEALTHCARE FACILITIES 103
6.3.3 RISING ADOPTION OF DIGITAL HEALTH TECHNOLOGIES FOR PEMPHIGUS VULGARIS TREATMENT MANAGEMENT 104
6.4 CHALLENGES 105
6.4.1 RISING CONCERNS OVER ADVERSE EFFECTS OF PEMPHIGUS VULGARIS MEDICATIONS 105
6.4.2 LACK OF REIMBURSEMENT AND COVERAGE POLICIES 106
7 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 107
7.1 OVERVIEW 108
7.2 TREATMENT 111
7.3 DIAGNOSIS 113
8 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 114
8.1 OVERVIEW 115
8.2 ADULTS 118
8.3 GERIATRIC 118
8.4 PEDIATRIC 119
9 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER 120
9.1 OVERVIEW 121
9.2 HOSPITALS 124
9.3 SPECIALTY CLINICS 124
9.4 RESEARCH INSTITUTES 125
9.5 OTHERS 125
10 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 126
10.1 OVERVIEW 127
10.2 HOSPITALS PHARMACY 130
10.3 RETAIL PHARMACY 130
10.4 ONLINE PHARMACY 131
11 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION 132
11.1 OVERVIEW 133
11.2 NORTH AMERICA 136
11.2.1 U.S. 139
11.2.2 CANADA 142
11.2.3 MEXICO 145
11.3 EUROPE 148
11.3.1 GERMANY 152
11.3.2 U.K. 156
11.3.3 FRANCE 159
11.3.4 ITALY 162
11.3.5 SPAIN 165
11.3.6 SWITZERLAND 168
11.3.7 TURKEY 172
11.3.8 RUSSIA 175
11.3.9 BELGIUM 178
11.3.10 NETHERLANDS 182
11.3.11 DENMARK 186
11.3.12 NORWAY 190
11.3.13 FINLAND 194
11.3.14 POLAND 198
11.3.15 SWEDEN 201
11.3.16 REST OF EUROPE 205
11.4 ASIA-PACIFIC 206
11.4.1 CHINA 210
11.4.2 INDIA 213
11.4.3 SOUTH KOREA 216
11.4.4 MALAYSIA 219
11.4.5 JAPAN 222
11.4.6 AUSTRALIA 225
11.4.7 SINGAPORE 228
11.4.8 THAILAND 231
11.4.9 INDONESIA 234
11.4.10 NEW ZEALAND 237
11.4.11 TAIWAN 240
11.4.12 PHILIPPINES 243
11.4.13 HONG KONG 246
11.4.14 REST OF ASIA-PACIFIC 249
11.5 SOUTH AMERICA 250
11.5.1 BRAZIL 255
11.5.2 ARGENTINA 259
11.5.3 COLOMBIA 263
11.5.4 PERU 267
11.5.5 URUGUAY 271
11.5.6 ECUADOR 275
11.5.7 PARAGUAY 279
11.5.8 VENEZUELA 283
11.5.9 BOLIVIA 287
11.5.10 REST OF SOUTH AMERICA 291
11.6 MIDDLE EAST AND AFRICA 292
11.6.1 SAUDI ARABIA 296
11.6.2 EGYPT 300
11.6.3 U.A.E. 303
11.6.4 SOUTH AFRICA 306
11.6.5 ISRAEL 310
11.6.6 BAHRAIN 313
11.6.7 KUWAIT 317
11.6.8 OMAN 320
11.6.9 QATAR 323
11.6.10 REST OF MIDDLE EAST AND AFRICA 326
12 GLOBAL PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 327
12.1 COMPANY SHARE ANALYSIS: GLOBAL 327
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 328
12.3 COMPANY SHARE ANALYSIS: EUROPE 329
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 330
13 SWOT ANALYSIS 331
14 COMPANY PROFILE 332
14.1 MERCK AND CO. INC. 332
14.1.1 COMPANY SNAPSHOT 332
14.1.2 REVENUE ANALYSIS 332
14.1.3 COMPANY SHARE ANALYSIS 333
14.1.4 PRODUCT PORTFOLIO 333
14.1.5 RECENT DEVELOPMENTS 334
14.2 SANOFI 335
14.2.1 COMPANY SNAPSHOT 335
14.2.2 REVENUE ANALYSIS 335
14.2.3 COMPANY SHARE ANALYSIS 336
14.2.4 PRODUCT PORTFOLIO 336
14.2.5 RECENT DEVELOPMENT 337
14.3 REGENERON PHARMACEUTICALS INC. 338
14.3.1 COMPANY SNAPSHOT 338
14.3.2 REVENUE ANALYSIS 338
14.3.3 COMPANY SHARE ANALYSIS 339
14.3.4 PRODUCT PORTFOLIO 339
14.3.5 RECENT DEVELOPMENTS 340
14.4 JOHNSON & JOHNSON SERVICES, INC. 341
14.4.1 COMPANY SNAPSHOT 341
14.4.2 REVENUE ANALYSIS 341
14.4.3 COMPANY SHARE ANALYSIS 342
14.4.4 PRODUCT PORTFOLIO 342
14.4.5 RECENT DEVELOPMENT 343
14.5 ASTRAZENECA 344
14.5.1 COMPANY SNAPSHOT 344
14.5.2 REVENUE ANALYSIS 344
14.5.3 COMPANY SHARE ANALYSIS 345
14.5.4 PRODUCT PORTFOLIO 345
14.5.5 RECENT DEVELOPMENT 346
14.6 ABBVIE INC. 347
14.6.1 COMPANY SNAPSHOT 347
14.6.2 REVENUE ANALYSIS 347
14.6.3 PRODUCT PORTFOLIO 348
14.6.4 RECENT DEVELOPMENT 349
14.7 ACCORD HEALTHCARE 351
14.7.1 COMPANY SNAPSHOT 351
14.7.2 PRODUCT PORTFOLIO 351
14.7.3 RECENT DEVELOPMENT 351
14.8 AMGEN INC. 352
14.8.1 COMPANY SNAPSHOT 352
14.8.2 REVENUE ANALYSIS 352
14.8.3 PRODUCT PORTFOLIO 353
14.8.4 RECENT DEVELOPMENT 354
14.9 ARTIVA BIOTHERAPEUTICS, INC. 355
14.9.1 COMPANY SNAPSHOT 355
14.9.2 REVENUE ANALYSIS 355
14.9.3 PRODUCT PIPELINE PORTFOLIO 356
14.9.4 RECENT DEVELOPMENT 356
14.10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 357
14.10.1 COMPANY SNAPSHOT 357
14.10.2 PRODUCT PORTFOLIO 357
14.10.3 RECENT DEVELOPMENT 357
14.11 BAXTER 358
14.11.1 COMPANY SNAPSHOT 358
14.11.2 REVENUE ANALYSIS 358
14.11.3 PRODUCT PORTFOLIO 359
14.11.4 RECENT DEVELOPMENT 359
14.12 BIOXPRESS THERAPEUTICS SA 360
14.12.1 COMPANY SNAPSHOT 360
14.12.2 PRODUCT PORTFOLIO 360
14.12.3 RECENT DEVELOPMENT 360
14.13 CABALETTA BIO INC. 361
14.13.1 COMPANY SNAPSHOT 361
14.13.2 REVENUE ANALYSIS 361
14.13.3 PRODUCT PORTFOLIO 361
14.13.4 RECENT DEVELOPMENT 362
14.14 CIPLA HEALTH LTD 363
14.14.1 COMPANY SNAPSHOT 363
14.14.2 PRODUCT PORTFOLIO 363
14.14.3 RECENT DEVELOPMENTS 363
14.15 CELLTRION 364
14.15.1 COMPANY SNAPSHOT 364
14.15.2 REVENUE ANALYSIS 364
14.15.3 PRODUCT PORTFOLIO 365
14.15.4 RECENT DEVELOPMENTS 366
14.16 CSL 367
14.16.1 COMPANY SNAPSHOT 367
14.16.2 REVENUE ANALYSIS 367
14.16.3 PRODUCT PORTFOLIO 368
14.16.4 RECENT DEVELOPMENT 368
14.17 DAEWOONG PHARMACEUTICAL CO.,LTD. 369
14.17.1 COMPANY SNAPSHOT 369
14.17.2 REVENUE ANALYSIS 369
14.17.3 PRODUCT PORTFOLIO 370
14.17.4 RECENT DEVELOPMENT 370
14.18 F. HOFFMANN- LA ROCHE LTD. 371
14.18.1 COMPANY SNAPSHOT 371
14.18.2 REVENUE ANALYSIS 371
14.18.3 PRODUCT PORTFOLIO 372
14.18.4 RECENT DEVELOPMENT/NEWS 372
14.19 FRESENIUS KABI AG 374
14.19.1 COMPANY SNAPSHOT 374
14.19.2 REVENUE ANALYSIS 374
14.19.3 PRODUCT PORTFOLIO 375
14.19.4 RECENT DEVELOPMENT 375
14.20 GSK PLC 377
14.20.1 COMPANY SNAPSHOT 377
14.20.2 REVENUE ANALYSIS 377
14.20.3 PRODUCT PORTFOLIO 378
14.20.4 RECENT DEVELOPMENT 378
14.21 GRIFOLS, S.A. 380
14.21.1 COMPANY SNAPSHOT 380
14.21.2 REVENUE ANALYSIS 380
14.21.3 PRODUCT PORTFOLIO 381
14.21.4 RECENT DEVELOPMENT 381
14.22 INCYTE 382
14.22.1 COMPANY SNAPSHOT 382
14.22.2 REVENUE ANALYSIS 382
14.22.3 PRODUCT PORTFOLIO 383
14.22.4 RECENT DEVELOPMENT 383
14.23 NOVARTIS AG 384
14.23.1 COMPANY SNAPSHOT 384
14.23.2 REVENUE ANALYSIS 384
14.23.3 PRODUCT PORTFOLIO 385
14.23.4 RECENT DEVELOPMENT 385
14.24 LILLY 386
14.24.1 COMPANY SNAPSHOT 386
14.24.2 REVENUE ANALYSIS 386
14.24.3 PRODUCT PORTFOLIO 387
14.24.4 RECENT DEVELOPMENT 387
14.25 OCTAPHARMA AG 388
14.25.1 COMPANY SNAPSHOT 388
14.25.2 REVENUE ANALYSIS 388
14.25.3 PRODUCT PORTFOLIO 389
14.25.4 RECENT DEVELOPMENT/NEWS 389
14.26 PFIZER INC. 390
14.26.1 COMPANY SNAPSHOT 390
14.26.2 REVENUE ANALYSIS 390
14.26.3 PRODUCT PORTFOLIO 391
14.26.4 RECENT DEVELOPMENT 391
14.27 RAKSHIT DRUGS PVT. LTD 392
14.27.1 COMPANY SNAPSHOT 392
14.27.2 PRODUCT PORTFOLIO 392
14.27.3 RECENT DEVELOPMENT 393
14.28 SUN PHARMACEUTICALS INDUSTRIES LTD. 394
14.28.1 COMPANY SNAPSHOT 394
14.28.2 REVENUE ANALYSIS 394
14.28.3 PRODUCT PORTFOLIO 395
14.28.4 RECENT DEVELOPMENT 395
14.29 TEVA PHARMACEUTICAL INDUSTRIES LTD 396
14.29.1 COMPANY SNAPSHOT 396
14.29.2 REVENUE ANALYSIS 396
14.29.3 PRODUCT PORTFOLIO 397
14.29.4 RECENT DEVELOPMENT 397
14.30 ZYDUS GROUP 399
14.30.1 COMPANY SNAPSHOT 399
14.30.2 REVENUE ANALYSIS 399
14.30.3 PRODUCT PORTFOLIO 400
14.30.4 RECENT DEVELOPMENT 401
15 QUESTIONNAIRE 402
16 RELATED REPORTS 405